Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Rodin Therapeutics Inc.

Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2013
Status: Acquired

BioCentury | Sep 30, 2022
Management Tracks

Sullivan becomes CBO at Prilenia 

Plus new CMO at Cellectis, and updates from Lyell, Adrestia, Mursla and more
BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

Lessons for industry from nearly 20 years of amyloid failures
BioCentury | Jan 11, 2019
Product R&D

Biomarkers’ road less traveled

Why FDA’s biomarker guidance means consortia will still be in the driver’s seat
BioCentury | Sep 22, 2017
Financial News

Rodin raises $27M in series B

BioCentury | Sep 19, 2017
Financial News

Hatteras names Witty partner

BioCentury | Sep 18, 2017
Financial News

Rodin raises $27M series B

BioCentury | Apr 14, 2016
Emerging Company Profile

Thinking about HDAC2

Rodin's safe, selective HDAC2 inhibitors for AD
BioCentury | Jan 11, 2016
Financial News

Rodin Therapeutics completes venture financing

Items per page:
1 - 10 of 27